Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Melanoma · Melanoma Stage III · Melanoma (Skin) · Melanoma Stage IV

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, United States
Contact: Study coordinator (Warren Chow, MD) · ucstudy@uci.edu · 877-827-8839

Study leads

Warren Chow, MD
Principal Investigator
Chao Family Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Pancreatic Cancer · Renal Cell Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies · Ovarian Cancer · T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · New York, United States

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Non Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE2

Darmstadt, Germany · Milan, Italy

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States